What are the criteria that distinguish intractable (refractory) migraine from non‑intractable migraine, and what are the recommended acute and preventive treatment strategies for each?

Distinguishing Intractable from Non-Intractable Migraine

Intractable (refractory) migraine is defined by failure of adequate trials of preventive medications from at least 2 of 4 drug classes (beta-blockers, anticonvulsants, tricyclics, calcium channel blockers) AND failure of adequate abortive trials (triptan, DHE, and NSAIDs or combination analgesics), with headaches causing significant functional impairment despite trigger modification—this is fundamentally different from non-intractable migraine which responds to standard first-line therapies 1.

Diagnostic Criteria for Intractable Migraine

The most widely referenced criteria require 1:

• Must meet ICHD criteria for migraine or chronic migraine
• Significant interference with function/quality of life despite lifestyle modifications
• Failed preventive trials: Inadequate response to medications from ≥2 of these 4 classes:
  • Beta-blockers (propranolol, metoprolol, atenolol, bisoprolol)
  • Anticonvulsants (topiramate, valproate)
  • Tricyclics (amitriptyline)
  • Calcium channel blockers (flunarizine, candesartan)
• Failed acute treatment trials: Both a triptan AND DHE (intranasal/injectable) AND either NSAIDs or combination analgesics
• Adequate trial definition: ≥2 months at optimal/maximum-tolerated dose (unless stopped early for adverse effects)

Key modifier: Document presence/absence of medication overuse, as this fundamentally changes management 1, 2.

Treatment Strategy for Non-Intractable Migraine

Acute Treatment

Follow a stepped approach 3, 4:

Mild-to-moderate attacks:

• NSAIDs + antiemetic as first-line
• If 3 consecutive attacks fail → advance to triptans

Moderate-to-severe attacks:

• Triptans as first-line 5, 3
• If suboptimal response → switch to different triptan
• After triptan failure → gepants or ditans 5, 4

Preventive Treatment

Standard tiered approach 3:

First-line: Beta-blockers (propranolol, metoprolol, atenolol, bisoprolol), topiramate, or candesartan

Second-line: Flunarizine, amitriptyline, or valproate (contraindicated in women of childbearing potential)

Third-line: CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) 3

Initiate preventive therapy when: Adversely affected ≥2 days/month despite optimized acute treatment 3.

Treatment Strategy for Intractable Migraine

Management requires deviation from standard evidence-based pathways 6, 2:

Acute/Symptomatic Treatment

Gepants are preferred first-line due to low medication overuse headache risk 6. Alternative options include:

• Triptans combined with NSAIDs or antiemetics
• Ditans (no vascular contraindications but more adverse effects)
• Avoid opioids and butalbital 5, 4

Bridge Therapy

For transitioning to preventive therapy 6:

• Corticosteroids (short courses)
• Long-acting triptans

Preventive Treatment

Prioritize migraine-specific medications over repurposed drugs due to superior tolerability 6:

1. CGRP monoclonal antibodies as preferred option (migraine-specific mechanism)
2. Botulinum toxin for chronic migraine specifically 5, 7
3. Consider combination preventive therapy 7
4. In truly refractory cases: neurostimulation devices 7, 2

Non-Pharmacological Approaches

Evidence supports 5, 3:

• Physical therapy with trigger point massage, mobilization techniques
• Aerobic exercise 2-3 times/week for 30-60 minutes
• Progressive strength training 3 times/week supervised
• Biobehavioral therapy and neuromodulatory devices as adjuncts

Critical Management Pitfalls

Medication overuse must be addressed first 1, 2—refractory migraine cannot be properly diagnosed or treated while medication overuse persists. This requires withdrawal protocols before reassessing treatment response.

Comorbidities limit treatment options 6—identify and manage psychiatric conditions, sleep disorders, and other pain conditions that perpetuate the refractory state.

Inadequate trial duration 1—many patients are labeled "refractory" without completing true adequate trials (≥2 months at therapeutic doses). Verify actual treatment history before proceeding to advanced therapies.

The distinction is dynamic, not static 6, 2—patients may achieve temporary improvement then relapse, requiring continuous monitoring and reassessment rather than assuming permanent refractory status.